Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted ...

Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle atrophy (SMA) progression and could be applied to other motoneuron diseases, ...

Paris, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024, 80% of the TSXV Venture 50™ companies operated ...

Patients with lung cancer, breast cancer, prostate cancer, cancer with an unknown primary site, or renal cancer are at high risk for the development of SCC by metastatic tumor. Spinal cord ...

Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...

A Rutgers professor studying the sense of touch and its role in movement, socialization and pain perception has been awarded ...

The spinal cord is the first point in the central nervous ... disorders such as Parkinson's disease and may contribute to the development of novel therapies in the long term.

Ossification of the posterior longitudinal ligament (OPLL) is a progressive spinal disease characterized by ectopic bone ...

A University of Newcastle research team has secured a $940,000 National Health and Medical Research Council (NHMRC) Ideas Grant to examine the role of ...